Table 4.
Effects of patient characteristics and treatment parameters on acute and late genitourinary (GU) toxicity in Fisher’s exact test and logistic regression analysis
| Characteristic | Effects on acute GU toxicity | Effects on late GU toxicity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fisher’s exact test |
Logistic regression model | Fisher’s exact test |
Logistic regression model | ||||||||
| P value | OR | 95% CI | P value | P value | OR | 95% CI | P value | ||||
| Age | 0.11 | 1.6 | 0.77–3.1 | 0.22 | 1 | 1.1 | 0.38–3.2 | 0.88 | |||
| Tumor stage | 0.055 | 0.53 | 0.26 –1.1 | 0.071 | 0.81 | 1.2 | 0.38–4.0 | 0.73 | |||
| Baseline IPSS | 0.0089 | 2.0 | 1.2–3.3 | 0.0089 | 0.88 | 1.6 | 0.72–3.4 | 0.27 | |||
| GU medications | 0.68 | 0.51 | 0.20–1.3 | 0.17 | 0.21 | 0.18 | 0.021–1.6 | 0.12 | |||
| Diabetes | 1 | 0.81 | 0.26–2.5 | 0.72 | 0.23 | NE | NE | NE | |||
| ADT | 0.33 | 0.57 | 0.28–1.2 | 0.12 | 0.35 | 1.5 | 0.46–4.8 | 0.50 | |||
| Prostate volume | 0.43 | 1.2 | 0.51–2.8 | 0.68 | 0.34 | 1.8 | 0.50–6.2 | 0.38 | |||
| PTV volume | 0.52 | 0.89 | 0.40–2.0 | 0.79 | 0.64 | 0.55 | 0.16–1.9 | 0.33 | |||
| PTV max. dose | 0.63 | 2.1 | 0.91–5.0 | 0.083 | 0.81 | 0.66 | 0.20–2.2 | 0.50 | |||
| Bladder V70 | 0.63 | 1.5 | 0.63–3.5 | 0.37 | 0.090 | 4.1 | 1.12–15 | 0.033 | |||
| Bladder V40 | 1 | 0.96 | 0.37–2.5 | 0.94 | 0.81 | 1.0 | 0.23–4.6 | 0.97 | |||
| Bladder V20 | 0.63 | 0.80 | 0.33–2.0 | 0.64 | 1 | 0.44 | 0.10–1.9 | 0.28 | |||
| Bladder max. dose | 0.27 | 0.43 | 0.18–1.0 | 0.053 | 0.81 | 1.4 | 0.43–4.6 | 0.57 | |||
In the analysis of the effects on acute GU toxicity, ADT means neoadjuvant ADT CI = confidence interval